OncoTargeting AB was founded to forward the lead compound 3-MeSO2-DDE toward a treatment for AdrenoCortical Carcinoma (ACC). To help companies with similar challenges in pharmaceutical research and development, OncoTargeting also offers Contract Reseach. The CRO and project parts of the company are kept as economically independent units.

Our facilities are located in Uppsala Business park, Sweden and include an efficient and well equipped lab for the offered range of services.